One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…

Kai-Xian Chen Biography and Net Worth

Director of Zai Lab

Kai-Xian Chen, Ph.D., joined our company as Director in August 2018. From 2007 to 2017, he served as a member of the National Committee of the Chinese People's Political Consultative Conference. From 2005 to 2014, Professor Chen served as President of Shanghai University of Traditional Chinese Medicine. From 2011 to 2018, Professor Chen served as President of the Shanghai Association for Science and Technology. Prior to that, from 1993 to 2004, Professor Chen served as Deputy Director and later, Director of Shanghai Institute of Materia Medica, or SIMM, Chinese Academy of Sciences. Professor Chen has as also served as Principal Scientist for two National Basic Research Programs by the Ministry of Science and Technology, or MOST. Since 2001, professor Chen has served successively as the member of the Chief Specialists Board and the deputy chief technical officer of the major science and technology projects "innovative drugs and modernization of traditional Chinese medicine" and "Innovative Drug Research & Development", where he participated in the organization and promotion of new drug research and development for the PRC's 10th-13th Five Year Plans. In 1999, Professor Chen was elected as a member of the Chinese Academy of Sciences. Prior to that, from 1985 to 1988, he conducted postdoctoral research at Institutde Biologie Physico-Chimique in Paris. Professor Chen started his academic career at SIMM as an Associate Professor, where he later reached the level of Full Professor.

Professor Chen received his Master and Ph.D. Degree at the Chinese Academy of Science, and his Bachelor of Science from Fudan University.

What is Kai-Xian Chen's net worth?: The estimated net worth of Kai-Xian Chen is at least $385,960.30 as of March 12th, 2021. Dr. Chen owns 24,662 shares of Zai Lab stock worth more than $385,960 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Chen may own. Learn More about Kai-Xian Chen's net worth.
How do I contact Kai-Xian Chen?: The corporate mailing address for Dr. Chen and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on Kai-Xian Chen's contact information.
Has Kai-Xian Chen been buying or selling shares of Zai Lab?: Kai-Xian Chen has not been actively trading shares of Zai Lab during the last ninety days. Most recently, Kai-Xian Chen sold 4,302 shares of the business's stock in a transaction on Friday, March 12th. The shares were sold at an average price of $142.53, for a transaction totalling $613,164.06. Following the completion of the sale, the director now directly owns 24,662 shares of the company's stock, valued at $3,515,074.86. Learn More on Kai-Xian Chen's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 2 times. They purchased a total of 9,000 shares worth more than $254,250.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 40,476 shares worth more than $940,803.05. The most recent insider tranaction occured on April, 4th when insider Joshua L Smiley sold 1,988 shares worth more than $31,151.96. Insiders at Zai Lab own 5.2% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 4/4/2024.

Kai-Xian Chen Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/12/2021	Sell	4,302	$142.53	$613,164.06	24,662

Kai-Xian Chen Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $15.74

$15.05

$15.82

50 Day Range

MA: $17.54

$13.72

$22.49

2 Week Range

Now: $15.74

$13.48

$39.50

Volume

515,424 shs

Average Volume

630,998 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

What is the 72-Hour Profit Surge?

From DTI | Ad

Click here now to get all the details.